Novo Nordisk Annual Report 2021
Contents
Introducing Novo Nordisk
Strategic Aspirations
Key risks Management
Consolidated statements
Additional information
Novo Nordisk Annual Report 2021 88
CO₂ emissions from operations (production, office buildings and
laboratories)
CO₂ emissions from operations cover consumption of power, fuel, heat and
steam at office buildings in Denmark, global production sites and
laboratories, and consumption of power in office buildings outside Denmark.
Emissions are calculated according to the GHG Protocol and based on
emission factors from the previous year.
CO, emissions from product distribution
CO₂ emissions from product distribution are calculated by external
transportation suppliers as the estimated emissions from product
distribution in metric tonnes. CO₂ emissions are calculated based on the
worldwide distribution of semi-finished and finished products, raw materials
and components by air, sea and road between production sites and from
production sites to subsidiaries, direct customers and importing
distributors. CO₂ emissions from product distribution from subsidiaries to
pharmacies, hospitals and wholesalers are not included. Due to the lack of
reliable emissions data from specific freight forwarders, an estimated 3% of
trucking emissions are not included in the scope.
CO, emissions from business flights
CO₂ emissions from business flights are estimated based on mileage and
emission factors for short-, medium- and long-haul flights along with
passenger class obtained from travel agencies. Currently, 85% of emissions
from flights are calculated based on data provided by travel agencies. The
remaining 15% emissions are extrapolated based on the average CO₂
emissions per employee.
CO, emissions from company cars
CO₂ emissions from company cars cover cars leased or owned by Novo
Nordisk. Emissions are calculated by multiplying emission factors by the
volumes of diesel and petrol used.
CO₂ emissions by scope 1, 2 and 3
Scope 1 emissions comprise direct CO2 emissions from sources that are
owned or controlled by Novo Nordisk A/S.
Scope 2 emissions comprise CO₂ emissions from purchased or acquired
electricity, cooling, heat and steam.
Scope 3 emissions only include CO, emissions from business flights and
product distribution. Other Scope 3 categories, e.g. purchased goods
and services, capital goods, waste generated in operations and employee
commuting, are not included.
7.5 Waste from production sites
1,000 tonnes
60
Waste from production sites
2021
2020
2019
Organic residues
143
108
89
Other (paper, cardboard, metals, etc.)
Total recycling
8
8
8
151
116
97
Ethanol waste
13
9
13
Other (various combustible waste)
Total waste with energy recovery
Water waste
9
5
22
15
18
5
5
5
2
4
3
7
9
8
1
1
1
181
141
124
Other
Total waste with no energy recovery
Total waste to landfill
Total waste
In 2021, waste from production sites increased by 28% due to increased
production. 96% of the total waste was either recycled, used for biogas
production or incinerated at plants where energy is used for heat and
power production.
The amount of waste recycled increased by 30% from 116,000 to 151,000
tonnes primarily driven by the production in Kalundborg, Denmark.
The amount of waste sent for energy recovery increased by 47% from
15,000 to 22,000 tonnes, primarily due to increased production volumes
and challenges in ethanol regeneration. Less than 1% of total waste was
sent to landfill.
In 2021, as in 2020, 14% of the waste was categorised as hazardous waste.
Accounting policies
Waste is measured as the sum of all the waste disposed of at production
sites based on weight receipts. Organic residues for recycling are waste
from the production of the active pharmaceutical ingredients, where the
energy is recovered in biogas plants and the digested slurry is used on local
farmland as fertiliser. Ethanol is recovered in internal regeneration plants
and re-used. Energy recovery is waste disposed of at waste-to-energy plants
and at a biogas plant. Waste with no energy recovery covers water waste
and other waste not suitable for other disposal methods, such as hazardous
waste for incineration and various other types of waste.
Section 8
Social performance
8.1 Patients reached with Novo Nordisk's Diabetes
care products
The estimated number of full-year patients reached with Novo Nordisk's
Diabetes care products increased from 32.8 million in 2020 to 34.6 million in
2021. This 5% increase was primarily driven by growth in the GLP-1 franchise
which increased by 1.3 million patients followed by the new-generation
insulin franchise which grew by 0.7 million patients.
In 2021, the estimated number of patients reached with Novo Nordisk's
Diabetes care products through the Access to Insulin Commitment was 1.7
million. Novo Nordisk also sold human insulin below the ceiling price of USD
3 in countries outside the commitment, reaching an estimated additional
2.2 million patients in 2021. During 2020, the ceiling price was lowered from
USD 4 to USD 3 which affects the comparability of 2021 and prior years.
Comparing 2021 and 2020 using the current ceiling price of USD 3, the
result is an estimated increase of 40,000 patients reached in 2021. Using
the previous ceiling price of USD 4, an estimated 3.4 million patients were
reached in 2021 compared to 3.2 million in 2020. In addition to offering
insulin at a low price, supply chain improvements and capacity building are
also important levers in ensuring access to affordable care for vulnerable
patients.
Through the Changing Diabetes in Children programme, 31,846 children
had been reached by the end of 2021, compared with 28,296 in 2020.
More than half of the 3,550 newly enrolled children were reached through
expansion of the programme in Ethiopia, Sudan, Kenya and Uganda.
Accounting policies
The number of full-year patients reached with Novo Nordisk's Diabetes care
products, excluding devices, is estimated by dividing Novo Nordisk's annual
sales volume by the annual usage dose per patient for each product class as
defined by the World Health Organization (WHO).
The number of full-year patients reached with Novo Nordisk's Diabetes care
products (human insulin in vials) via the Access to Insulin Commitment is
estimated by dividing Novo Nordisk's annual sales volume by the annual
usage dose per patient reached via the Access to Insulin Commitment as
defined by WHO.View entire presentation